A detailed history of Klingenstein Fields & CO LP transactions in Eli Lilly & CO stock. As of the latest transaction made, Klingenstein Fields & CO LP holds 93,662 shares of LLY stock, worth $85.2 Million. This represents 3.55% of its overall portfolio holdings.

Number of Shares
93,662
Previous 94,807 1.21%
Holding current value
$85.2 Million
Previous $73.8 Million 14.97%
% of portfolio
3.55%
Previous 3.09%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 01, 2024

SELL
$724.87 - $909.04 $829,976 - $1.04 Million
-1,145 Reduced 1.21%
93,662 $84.8 Million
Q1 2024

Apr 29, 2024

SELL
$592.2 - $792.28 $1.04 Million - $1.39 Million
-1,757 Reduced 1.82%
94,807 $73.8 Million
Q4 2023

Feb 01, 2024

SELL
$525.19 - $619.13 $607,119 - $715,714
-1,156 Reduced 1.18%
96,564 $56.3 Million
Q3 2023

Oct 27, 2023

SELL
$434.7 - $599.3 $18,257 - $25,170
-42 Reduced 0.04%
97,720 $52.5 Million
Q2 2023

Aug 01, 2023

SELL
$350.74 - $468.98 $292,166 - $390,660
-833 Reduced 0.84%
97,762 $45.8 Million
Q1 2023

Apr 28, 2023

SELL
$310.63 - $364.82 $284,847 - $334,539
-917 Reduced 0.92%
98,595 $33.9 Million
Q4 2022

Feb 02, 2023

SELL
$321.55 - $374.67 $589,401 - $686,770
-1,833 Reduced 1.81%
99,512 $36.4 Million
Q3 2022

Oct 28, 2022

SELL
$296.48 - $337.87 $741,200 - $844,675
-2,500 Reduced 2.41%
101,345 $32.8 Million
Q2 2022

Aug 01, 2022

SELL
$278.73 - $327.27 $275,663 - $323,670
-989 Reduced 0.94%
103,845 $33.7 Million
Q1 2022

Apr 27, 2022

SELL
$234.69 - $291.66 $320,821 - $398,699
-1,367 Reduced 1.29%
104,834 $30 Million
Q4 2021

Jan 31, 2022

SELL
$224.85 - $279.04 $1.1 Million - $1.37 Million
-4,910 Reduced 4.42%
106,201 $29.3 Million
Q3 2021

Oct 26, 2021

SELL
$221.6 - $272.71 $440,319 - $541,874
-1,987 Reduced 1.76%
111,111 $25.7 Million
Q2 2021

Jul 26, 2021

SELL
$180.55 - $233.54 $91,899 - $118,871
-509 Reduced 0.45%
113,098 $26 Million
Q1 2021

Apr 29, 2021

SELL
$164.32 - $212.72 $200,306 - $259,305
-1,219 Reduced 1.06%
113,607 $21.2 Million
Q4 2020

Feb 02, 2021

SELL
$130.46 - $172.63 $52,184 - $69,052
-400 Reduced 0.35%
114,826 $19.4 Million
Q3 2020

Oct 30, 2020

SELL
$146.22 - $169.13 $413,802 - $478,637
-2,830 Reduced 2.4%
115,226 $17.1 Million
Q2 2020

Aug 03, 2020

SELL
$136.42 - $164.18 $196,717 - $236,747
-1,442 Reduced 1.21%
118,056 $19.4 Million
Q1 2020

May 07, 2020

SELL
$119.05 - $147.35 $77,382 - $95,777
-650 Reduced 0.54%
119,498 $16.6 Million
Q4 2019

Feb 04, 2020

SELL
$106.92 - $132.43 $4,383 - $5,429
-41 Reduced 0.03%
120,148 $15.8 Million
Q2 2019

Aug 12, 2019

SELL
$110.79 - $129.32 $16,507 - $19,268
-149 Reduced 0.12%
120,189 $13.3 Million
Q1 2019

Apr 29, 2019

SELL
$111.31 - $131.02 $20.8 Million - $24.5 Million
-187,248 Reduced 60.88%
120,338 $15.6 Million
Q4 2018

Jan 22, 2019

SELL
$105.9 - $118.64 $58,668 - $65,726
-554 Reduced 0.18%
307,586 $35.6 Million
Q3 2018

Nov 01, 2018

SELL
$85.86 - $107.31 $661,122 - $826,287
-7,700 Reduced 2.44%
308,140 $33.1 Million
Q1 2018

May 01, 2018

SELL
$74.21 - $87.6 $85,341 - $100,740
-1,150 Reduced 0.36%
315,840 $24.4 Million
Q4 2017

Jan 30, 2018

SELL
$81.94 - $87.89 $127,007 - $136,229
-1,550 Reduced 0.49%
316,990 $26.8 Million
Q3 2017

Nov 01, 2017

BUY
$77.07 - $85.54 $24.5 Million - $27.2 Million
318,540
318,540 $27.2 Million

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $864B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Klingenstein Fields & CO LP Portfolio

Follow Klingenstein Fields & CO LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Klingenstein Fields & CO LP, based on Form 13F filings with the SEC.

News

Stay updated on Klingenstein Fields & CO LP with notifications on news.